ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPGNasdaq
$18.74
↓ -8.1%Jul 17 close · end-of-day
Price
1Y↓ -51.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Our headquarters and principal executive office is located in Suzhou, Jiangsu, China.
- CEO
- Dajun Yang
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 600
- Website
- www.ascentage.com
Management & directors
- Yang DajunChairman and CEO
- Zhai YifanChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-21 | Zhai Yifan· Chief Medical Officer | Option exercise | 92,746 | $0.00 | $0.00 | filing |
| 2026-05-21 | Zhai Yifan· Chief Medical Officer | Option exercise | 95,575 | $0.00 | $0.00 | filing |
| 2026-05-21 | Yang Dajun· Chairman and CEO | Option exercise | 95,575 | $0.00 | $0.00 | filing |
| 2026-05-21 | Yang Dajun· Chairman and CEO | Option exercise | 92,746 | $0.00 | $0.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.